Pritumumab

N/A

Report date: 2023/08/23 16:41:26

Base Information

Drug NamePritumumab
Drug Alias Name普立木单抗Monoclonal antibody ACA 11CLN-IgGCLNH-11ACA-11
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsVimentin modulatorsT lymphocytes stimulants +[4] 
TargetsVimentin
Therapy Area/IndicationsBrain metastasesBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California
China Registration ClassN/A

Develop Information

Active CompaniesBioRay Pharmaceutical LtdNascent Biotech Inc
Inactive CompaniesN/A
Active IndicationsBrain metastasesBrain Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank